Biotie regains rights to develop PDE10 inhibitors for CNS disorders
(Thomson Reuters ONE) -
BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 15 October 2010 at 12.15
Biotie regains rights to develop PDE10 inhibitors for CNS disorders
Biotie announced today that it will regain rights to compounds relating to PDE10
inhibition for the treatment of CNS disorders, including schizophrenia. The
compounds were the subject of a four-year collaboration with Wyeth (which was
acquired by Pfizer in 2009) which started in 2006 and which yielded several
promising PDE10 inhibitors that have demonstrated activity in pre-clinical
models of schizophrenia.
Timo Veromaa, Chief Executive Officer of Biotie commented, "We are excited about
PDE10 as a novel target for the treatment of schizophrenia and other disorders
of the central nervous system. We have had a succesful research collaboration
with Wyeth, and then Pfizer, and together we have generated supportive data for
this class. We are now in a position to pursue novel clinical candidates going
forward."
Turku, 15 October 2010
Biotie Therapies Corp.
Timo Veromaa
President and CEO
For further information, please contact:
Virve Nurmi, Investor Relations Manager
tel. +358 2 274 8900, e-mail: virve.nurmi(at)biotie.com
www.biotie.com
Distribution:
NASDAQ OMX Helsinki Ltd
Main Media
ABOUT BIOTIE THERAPIES
Biotie is a drug discovery and development company focused on central nervous
system and inflammatory diseases. It has a broad range of innovative small
molecule and biological drug candidates at different stages of clinical and pre-
clinical development. Biotie's products address diseases with high unmet medical
need and significant market potential, including addiction and psychotic
disorders, rheumatoid arthritis, psoriasis and chronic obstructive pulmonary
disease (COPD). The most advanced product, nalmefene for alcohol dependence, is
currently in phase III clinical development by licensing partner H. Lundbeck
A/S.
Biotie has operations in Turku, Finland and Radebeul, Germany.
Biotie shares are listed on NASDAQ OMX Helsinki Ltd.
For more information, please refer to www.biotie.com
[HUG#1452271]
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Biotie Therapies Oyj via Thomson Reuters ONE
Unternehmensinformation / Kurzprofil:
Datum: 15.10.2010 - 11:15 Uhr
Sprache: Deutsch
News-ID 45688
Anzahl Zeichen: 0
contact information:
Town:
Turku
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 252 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Biotie regains rights to develop PDE10 inhibitors for CNS disorders"
steht unter der journalistisch-redaktionellen Verantwortung von
Biotie Therapies Oyj (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
